- Home
- BMEA vs FRD Comparison
BMEA vs FRD Comparison
Compare BMEA & FRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- FRD
- Stock Information
- Founded
- BMEA 2017
- FRD 1965
- Country
- BMEA United States
- FRD United States
- Employees
- BMEA N/A
- FRD N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- FRD Steel/Iron Ore
- Sector
- BMEA Health Care
- FRD Industrials
- Exchange
- BMEA Nasdaq
- FRD Nasdaq
- Market Cap
- BMEA 103.5M
- FRD 114.4M
- IPO Year
- BMEA 2021
- FRD N/A
- Fundamental
- Price
- BMEA $1.83
- FRD $17.53
- Analyst Decision
- BMEA Strong Buy
- FRD
- Analyst Count
- BMEA 10
- FRD 0
- Target Price
- BMEA $17.70
- FRD N/A
- AVG Volume (30 Days)
- BMEA 683.1K
- FRD 26.2K
- Earning Date
- BMEA 08-05-2025
- FRD 08-07-2025
- Dividend Yield
- BMEA N/A
- FRD 0.91%
- EPS Growth
- BMEA N/A
- FRD N/A
- EPS
- BMEA N/A
- FRD 1.21
- Revenue
- BMEA N/A
- FRD $464,826,000.00
- Revenue This Year
- BMEA N/A
- FRD N/A
- Revenue Next Year
- BMEA N/A
- FRD N/A
- P/E Ratio
- BMEA N/A
- FRD $14.47
- Revenue Growth
- BMEA N/A
- FRD N/A
- 52 Week Low
- BMEA $1.29
- FRD $12.24
- 52 Week High
- BMEA $13.07
- FRD $18.48
- Technical
- Relative Strength Index (RSI)
- BMEA 56.62
- FRD 61.48
- Support Level
- BMEA $1.51
- FRD $16.46
- Resistance Level
- BMEA $1.86
- FRD $17.63
- Average True Range (ATR)
- BMEA 0.10
- FRD 0.68
- MACD
- BMEA 0.03
- FRD 0.14
- Stochastic Oscillator
- BMEA 91.67
- FRD 89.88
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About FRD Friedman Industries Inc.
Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.